Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience

Future Oncology · Published 2026-07-30 · DOI 10.1080/14796694.2026.2709201

Free full text

Authors (5)

Riddhi A. Babel, Stephen V. Liu, Tao Fan, Mayur M. Amonkar, Vamsidhar Velcheti

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Babel, R., Liu, S., Fan, T., et al. (2026). Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience. Future Oncology. https://doi.org/10.1080/14796694.2026.2709201

Related articles

• First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) · Cancer Immunology, Immunotherapy · 2023 · Cites or is cited by this article
• PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021 · Journal of Immunotherapy and Precision Oncology · 2025 · Cites or is cited by this article
• Real-World Outcomes of Pembrolizumab in Advanced Melanoma by Age and Sex: A National Population-Based Study · Targeted Oncology · 2025 · Cites or is cited by this article
• Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · Future Oncology · 2026 · Same journal
• Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · Future Oncology · 2026 · Same journal
• Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · Future Oncology · 2026 · Same journal
• Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · Future Oncology · 2026 · Same journal
• IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · Future Oncology · 2026 · Same journal
• Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · Future Oncology · 2026 · Same journal
• Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · Future Oncology · 2026 · Same journal